To receive future news releases direct to your inbox, subscribe by emailing firstname.lastname@example.org.
Historical news and financial information can also be found at www.sedar.com under the Company’s profile.
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
September 27, 2019
Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
September 23, 2019
Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)
May 6, 2019
Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
April 18, 2019
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
April 1, 2019
Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone
March 27, 2019
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
March 18, 2019